58
Participants
Start Date
March 2, 2020
Primary Completion Date
January 24, 2023
Study Completion Date
January 25, 2024
SF2a-TT15 Shigella Vaccine
0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
Placebo
0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
S. flexneri 2a strain 2457T Challenge Agent
Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.
University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore
University of Maryland, Baltimore
OTHER